• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 4Evidence profile of comparisons of targeted immune modulators for the treatment of psoriatic arthritis in adults

Number of studies/patientsDesignQualityConsistencyDirectnessMagnitude of effectOther modifying factorsOverall grade of the evidence
Adalimumab compared with etanercept
 Outcome: Health outcomes
  Indirect: 1
  N ≈ 982
MA with indirect comparison of placebo trials*FairYesIndirectACR 20 RR (95% CI)
0.63 (0.22, 1.81)
PsARC RR (95% CI)
1.35 (0.67, 2.73)
NoneInsufficient
Adalimumab compared with infliximab
 Outcome: Health outcomes
  Indirect: 1
  N ≈ 982
MA with indirect comparison of placebo trials*FairYesIndirectACR 20 RR (95% CI)
0.60 (0.30, 1.20)
PsARC RR (95% CI)
0.77 (0.53, 1.13)
NoneInsufficient
Etanercept compared with infliximab
 Outcome: Health outcomes
  Indirect: 1
  N ≈ 982
MA with indirect comparison of placebo trials*FairYesIndirectACR 20 RR (95% CI)
0.96 (0.33, 2.76)
PsARC RR (95% CI)
0.57 (0.28, 1.17)
NoneInsufficient
Adalimumab compared with etanercept compared with infliximab
Outcome: Health outcomes
  Indirect: 1
  N ≈ 982
MA with indirect comparison of placebo trials*GoodYesIndirectProbability of PsARC response:
adalimumab 59%
(44%–71%)
etanercept 71%
(57%–83%)
infliximab 80%
(67%–87%)
NoneInsufficient
Outcome: Quality of life
  Direct: 1 N=596Observational studyFairNADirectImprovement in QoL similar for patients taking Adalimumab, etanercept, and infliximabNoneInsufficient
*

Indirect comparisons performed using adjusted indirect method{Saad, 2008 #3649} or Bayesian methods{Rodgers, 2011 #6750} Probability of response (95% credibility interval) using Bayesian indirect methods)

ACR 20/50/70, American College of Rheumatology, numbers refer to percentage improvement; MA, meta-analysis; NA, not applicable; PsARC, Psoriatic Arthritis Response Criteria; QoL: Quality of Life: RR, relative risk.

Indirect comparisons performed using adjusted indirect method{Saad, 2008 #3649} or Bayesian methods{Rodgers, 2011 #6750} Probability of response (95% credibility interval) using Bayesian indirect methods)

From: Appendix I, Evidence profiles

Cover of Drug Class Review: Targeted Immune Modulators
Drug Class Review: Targeted Immune Modulators: Final Update 3 Report [Internet].
Thaler KJ, Gartlehner G, Kien C, et al.
Portland (OR): Oregon Health & Science University; 2012 Mar.
Copyright © 2012, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.